截至2026年2月5日收盘，奥克股份(300082)报收于9.56元，下跌3.43%，换手率1.81%，成交量12.28万 手，成交额1.19亿元。 董秘最新回复 董秘： 尊敬的投资者，您好！聚乙二醇3350散、复方聚乙二醇（3350）电解质散等用于便秘治疗或术 前清肠的药物中。公司自主开发的原料药聚乙二醇3350目前处于申报审评审批阶段，尚未上市销售。感 谢您的关注！ 投资者： 请问公司催化剂白银回收技术是自主的吗？有推广价值吗？ 董秘： 尊敬的投资者，您好！公司依据环保要求，寻找有资质处置企业实施含银废催化剂处置。感谢 您的关注！ 投资者： 公司聚乙二醇除了原料药和锂电，25年又开发了光刻胶原料，请问26年有无进一步高精尖用 途的研发安排或者销售计划？ 董秘： 尊敬的投资者，您好！公司持续跟踪行业技术发展和客户需求，积极对接下游客户需要研发相 关产品和开发技术，如涉及需要披露信息，公司将依法合规予以披露。敬请您持续关注。感谢您的关 注！ 投资者： 公司新增近千吨异氰尿酸酯的用途有哪些 投资者： 董秘您好，请问奥克股份2025年扣非后利润为什么还没有转正？传统产品和新能源材料产品 的销售情况？peg产品的销 ...

Core Viewpoint - The company, KuaHua Pharmaceutical, reported a significant decline in net profit and revenue in the first half of 2025, but showed signs of stabilization in Q2, with a focus on channel inventory management and strategic reforms to prepare for future growth [2][3][10]. Financial Performance - In the first half of 2025, KuaHua Pharmaceutical achieved a net profit of 81.31 million yuan and a net profit of 48.19 million yuan after deducting non-recurring items, both showing a significant decline compared to the same period last year [2]. - The pharmaceutical manufacturing industry experienced a revenue decline of 1.2% year-on-year, with total profits down 2.8% [2]. Inventory Management - The company actively managed channel inventory, leading to a reduction in inventory pressure despite short-term impacts on revenue and profit [3][4]. - The inventory management strategy has shown positive results, with channel inventory returning to a healthier state, indicating potential for revenue growth as demand recovers [4]. Product Strategy - KuaHua Pharmaceutical is focusing on the "one elderly, one child, one woman" strategy, enhancing its product offerings in these core areas [5][7]. - New product launches, such as ibuprofen suspension for children and polyethylene glycol for adults, are aimed at filling market gaps and enhancing competitiveness [7]. Market Opportunities - The company is expanding into the health sector and optimizing its channel structure to diversify growth avenues and reduce reliance on OTC drug sales [8]. - External factors, such as childcare subsidies and stricter drug regulations, are expected to boost demand for children's medications and strengthen the competitive position of leading companies like KuaHua Pharmaceutical [9][10]. Future Outlook - The combination of internal improvements and favorable external conditions suggests that KuaHua Pharmaceutical is well-positioned for a recovery in performance, with potential for accelerated growth as the industry stabilizes [10].